The two 90-day rings achieved higher dapivirine concentrations in blood plasma and vaginal fluid, with levels that were 1.3 to 1.9 times higher in plasma and 1.5 to 2.9 times higher in vaginal fluid. All three rings reported no safety concerns. The study enrolled 49 HIV-negative women, who were randomly assigned the 100mg ring, the 200mg ring or a monthly version of the ring which contains 25mg of the drug.
